Portal de Periódicos da CAPES

A Thermostable mRNA Vaccine against COVID-19

2020; Cell Press; Volume: 182; Issue: 5 Linguagem: Inglês

10.1016/j.cell.2020.07.024

1097-4172

Na-Na Zhang, Xiao-Feng Li, Yong‐Qiang Deng, Hui Zhao, Yi-Jiao Huang, Guan Yang, Weijin Huang, Peng Gao, Chao Zhou, Rong-Rong Zhang, Yan Guo, Shi-Hui Sun, Hang Fan, Shu-Long Zu, Qi Chen, Qi He, Tian-Shu Cao, Xing‐Yao Huang, Hong-Ying Qiu, Jian-Hui Nie, Yuhang Jiang, Hua-Yuan Yan, Qing Ye, Xia Zhong, Xia-Lin Xue, Zhen-Yu Zha, Dongsheng Zhou, Xiao Yang, You-Chun Wang, Bo Ying, Cheng‐Feng Qin,

Viral gastroenteritis research and epidemiology

There is an urgent need for vaccines against coronavirus disease 2019 (COVID-19) because of the ongoing SARS-CoV-2 pandemic. Among all approaches, a messenger RNA (mRNA)-based vaccine has emerged as a rapid and versatile platform to quickly respond to this challenge. Here, we developed a lipid nanoparticle-encapsulated mRNA (mRNA-LNP) encoding the receptor binding domain (RBD) of SARS-CoV-2 as a vaccine candidate (called ARCoV). Intramuscular immunization of ARCoV mRNA-LNP elicited robust neutralizing antibodies against SARS-CoV-2 as well as a Th1-biased cellular response in mice and non-human primates. Two doses of ARCoV immunization in mice conferred complete protection against the challenge of a SARS-CoV-2 mouse-adapted strain. Additionally, ARCoV is manufactured as a liquid formulation and can be stored at room temperature for at least 1 week. ARCoV is currently being evaluated in phase 1 clinical trials.